Abstract
THU-073 - Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have